Genmab A (GMAB) Operating Leases (2019 - 2026)

Genmab A (GMAB) has reported Operating Leases for 8 consecutive years, with $120.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 9.09% year-over-year to $120.0 million; the trailing twelve-month figure through Jun 2026 stood at $120.0 million (down 9.09% YoY), and the FY2025 full-year result was $134.0 million, up 2.29% from the prior year.
• Operating Leases eased to $120.0 million in Q2 2026 per GMAB's latest filing, from $125.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $188.3 million in Q4 2024 and bottomed at $38.2 million in Q1 2022.
• Historically, Operating Leases has averaged $92.4 million across 5 years, with a median of $86.0 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Operating Leases soared 194.79% in 2024, then dropped 28.84% in 2025.
• Over 5 years, Operating Leases stood at $48.8 million in 2022, then surged by 30.89% to $63.9 million in 2023, then jumped by 194.79% to $188.3 million in 2024, then declined by 28.84% to $134.0 million in 2025, then decreased by 10.45% to $120.0 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $120.0 million, $125.0 million, and $134.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.